Stock A138610 NIBEC CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NIBEC Co., Ltd.

Equities

A138610

KR7138610001

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
17,430 KRW +1.40% Intraday chart for NIBEC Co., Ltd. -0.11% -19.49%
2022 NIBEC Co., Ltd. announced that it has received KRW 25 billion in funding from a group of investors CI
2022 NIBEC Co., Ltd. announced that it expects to receive KRW 25 billion in funding from a group of investors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 69,092 109,923 428,799 288,672 188,694 219,416
Enterprise Value (EV) 1 76,056 103,577 415,839 285,260 174,583 214,359
P/E ratio -16.3 x -35.8 x -118 x -50.3 x -50 x -
Yield - - - - - -
Capitalization / Revenue 13.3 x 11.8 x 67.5 x 21.2 x 8.71 x 14 x
EV / Revenue 14.6 x 11.2 x 65.4 x 20.9 x 8.06 x 13.7 x
EV / EBITDA -40.8 x 154 x -342 x 619 x 46.6 x 187 x
EV / FCF -18.1 x -18.5 x -112 x -72.6 x 63.6 x -45.1 x
FCF Yield -5.52% -5.39% -0.89% -1.38% 1.57% -2.22%
Price to Book 6.53 x 4.01 x 13.5 x 10.6 x 5.71 x -
Nbr of stocks (in thousands) 6,368 9,903 9,903 9,903 9,957 10,135
Reference price 2 10,850 11,100 43,300 29,150 18,950 21,650
Announcement Date 3/1/19 12/31/20 3/1/21 12/31/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5,208 9,287 6,357 13,625 21,670 15,704
EBITDA 1 -1,865 670.6 -1,216 460.5 3,747 1,147
EBIT 1 -3,461 -1,111 -3,270 -2,108 645.7 -2,230
Operating Margin -66.46% -11.97% -51.44% -15.47% 2.98% -14.2%
Earnings before Tax (EBT) 1 -4,048 -2,599 -4,610 -5,653 -4,623 -6,181
Net income 1 -4,146 -2,727 -3,638 -5,740 -3,766 -6,284
Net margin -79.61% -29.36% -57.22% -42.13% -17.38% -40.02%
EPS 2 -665.4 -309.6 -367.3 -579.6 -378.8 -
Free Cash Flow 1 -4,200 -5,586 -3,720 -3,928 2,746 -4,749
FCF margin -80.66% -60.15% -58.52% -28.83% 12.67% -30.24%
FCF Conversion (EBITDA) - - - - 73.29% -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/1/19 12/31/20 3/1/21 12/31/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 6,964 - - - - -
Net Cash position 1 - 6,346 12,960 3,412 14,111 5,057
Leverage (Debt/EBITDA) -3.733 x - - - - -
Free Cash Flow 1 -4,200 -5,586 -3,720 -3,928 2,746 -4,749
ROE (net income / shareholders' equity) -36.2% -14.4% -12.3% -19.4% -12.5% -20.3%
ROA (Net income/ Total Assets) -9% -2.39% -4.6% -2.48% 0.65% -2.02%
Assets 1 46,063 113,933 79,044 231,657 -579,899 310,575
Book Value Per Share 2 1,661 2,767 3,215 2,761 3,321 -
Cash Flow per Share 2 135.0 455.0 2,172 1,570 2,736 -
Capex 1 968 2,011 1,783 1,640 977 3,628
Capex / Sales 18.59% 21.65% 28.04% 12.04% 4.51% 23.1%
Announcement Date 3/1/19 12/31/20 3/1/21 12/31/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Medical Devices

1st Jan change Capi.
NIBEC CO., LTD. Stock NIBEC Co., Ltd.
-19.49% 128M
MIMEDX GROUP, INC. Stock MiMedx Group, Inc.
-28.62% 925M
COLLPLANT BIOTECHNOLOGIES LTD. Stock CollPlant Biotechnologies Ltd.
-6.57% 67.46M
KIM FOREST ENTERPRISE CO., LTD. Stock Kim Forest Enterprise Co., Ltd.
+5.69% 60.58M
BONUS BIOGROUP LTD. Stock Bonus BioGroup Ltd.
+0.60% 51.45M
Bio Medical Devices
  1. Stock Market
  2. Equities
  3. A138610 Stock
  4. Financials NIBEC Co., Ltd.